The Innovation Medicine > 2023 Vol. 1 > No. 1 > 100006
Next Article Previous Article
COMMENTARY   Open Access     Cite

Lilly's Donanemab, will it be the light at the end of the tunnel?

  • 1.

    School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China

  • 2.

    Department of Good Clinical Practice, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China

More Information
  • Corresponding author: wangying@hmc.edu.cn
  • Received Date:  08 May 2023
    Accepted Date:  30 May 2023
    Published Online:  31 May 2023
The Innovation Medicine  1(1),  https://doi.org/10.59717/j.xinn-med.2023.100006  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Mintun, M.A., Lo, A.C., Duggan Evans, C., et al. (2021). Donanemab in early Alzheimer's Disease. N. Engl. J. Med. 384: 1691−1704. DOI: 10.1056/NEJMoa2100708.

    View in Article CrossRef Google Scholar

    [2] Shcherbinin, S., Evans, C.D., Lu, M., et al. (2022). Association of amyloid reduction after donanemab treatment with Tau pathology and clinical outcomes: The TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 79: 1015−1024. DOI: 10.1001/jamaneurol.2022.2793.

    View in Article CrossRef Google Scholar

    [3] Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease. Lilly, https://investor.lilly.com/news-releases/news-release-details/lilly-shares-positive-donanemab-data-first-active-comparator.

    View in Article Google Scholar

    [4] Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease. Lilly, https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-significantly-slowed-cognitive-and-functional

    View in Article Google Scholar

    [5] Gueorguieva, I., Willis, B.A., Chua, L., et al. (2023). Donanemab population pharmacokinetics, amyloid plaque reduction, and safety in participants with Alzheimer's Disease. Clin. Pharmacol. Ther. 113: 1258-1267. DOI: 10.1002/cpt.2875.

    View in Article Google Scholar

    • CITED BY

  • Cite this article:

    Dong J. and Wang Y. (2023). Lilly's Donanemab, will it be the light at the end of the tunnel? The Innovation Medicine 1(1), 100006. https://doi.org/10.59717/j.xinn-med.2023.100006
    Dong J. and Wang Y. (2023). Lilly's Donanemab, will it be the light at the end of the tunnel? The Innovation Medicine 1(1), 100006. https://doi.org/10.59717/j.xinn-med.2023.100006

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(2362) PDF downloads(844) Cited by(0)

Relative Articles

Article Contents
ABOUT THIS ARTICLE

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    Journal links

    {{newsColumn.name}}

    Stay connected

    Copyright © Innovation Press